— Know what they know.
Not Investment Advice

ENVB

Enveric Biosciences, Inc.
1W: -2.0% 1M: -10.4% 3M: -62.4% YTD: -46.3% 1Y: -90.6% 3Y: -99.4% 5Y: -100.0%
$1.97
+0.02 (+1.03%)
After Hours: $1.99 (+0.02, +1.02%)
NASDAQ · Healthcare · Biotechnology · $1.2M · Alpha Radar Sell · Power 31
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$1.2M
52W Range1.82-21.24
Volume20,592
Avg Volume377,989
Beta0.30
Dividend
Analyst Ratings
3 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOJoseph Edward Tucker
Employees5
SectorHealthcare
IndustryBiotechnology
IPO Date2015-05-04
4851 Tamiami Trail North
Naples, FL 34103
US
239 302 1707
About Enveric Biosciences, Inc.

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Recent Insider Trades

NameTypeSharesPriceDate
Coveney Kevin Michae A-Award 74,150 2025-05-08
Facchini Peter J. A-Award 24,717 2025-05-08
Tucker Joseph Edward A-Award 98,866 2025-05-08
DeWitt Sheila A-Award 27,845 2024-10-09
Kegler George A. A-Award 47,733 2024-10-09

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms